Lixin Song

Title: Lixin Song: Innovator in Immunotherapeutic Fusion Proteins

Introduction

Lixin Song is a prominent inventor based in Jiangsu, China. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins for immunotherapeutic applications. His innovative work has the potential to enhance cancer treatment strategies.

Latest Patents

Lixin Song holds a patent for a "Fusion protein dimer using antibody Fc region as backbone and use thereof." This invention involves a fusion protein dimer that utilizes an antibody Fc region as its backbone. The structure comprises a first and a second polypeptide chain, with each chain containing an antibody Fc region and one or more single-domain antibodies. Additionally, the polypeptide chains may include a cytokine fused to the Fc region, enhancing the therapeutic potential of the fusion protein. This innovation not only increases the activity of single-domain antibodies but also significantly improves the biological activity of cytokines, thereby offering better anti-tumor potential.

Career Highlights

Lixin Song is currently associated with Nanjing Genscript Biotech Co., Ltd., where he continues to advance his research in biotechnology. His work focuses on developing novel therapeutic strategies that leverage the specificity of antibodies for targeted drug delivery.

Collaborations

Lixin collaborates with notable colleagues, including Wang Zhang and Dongliang Wang, who contribute to his research endeavors and help in the advancement of innovative solutions in the field.

Conclusion

Lixin Song's contributions to the field of immunotherapy through his innovative fusion protein dimer represent a significant advancement in cancer treatment. His work exemplifies the potential of biotechnology to improve therapeutic outcomes for patients.